



NEWS RELEASE

BIOSYENT ANNOUNCES INTRODUCTION OF NEW Feramax[®] Pd

FOR IMMEDIATE RELEASE

OCTOBER 5, 2020

MISSISSAUGA, ONTARIO (October 5, 2020) BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce the introduction of Feramax[®] Pd, a new oral iron supplement formulation, by its subsidiary BioSyent Pharma Inc. Feramax[®] Pd is a patented delivery system for the treatment of iron deficiency anemia and will be the foundation of future product developments.

BioSyent Pharma has a deep expertise and experience in the iron deficiency anemia therapy and prevention market, and in collaboration with its manufacturing partner, has developed a new proprietary formulation that will serve the needs of patients that suffer from low blood iron levels.

“We are excited about this new patented Feramax[®] Pd formulation which forms the platform for future product innovation,” commented René Goehrum, President and CEO of BioSyent Inc. “This introduction furthers BioSyent’s commitment to iron deficiency management and enables us to better meet the needs of healthcare professionals and patients through continued investment in the brand. Later this year we’ll be sharing news of the first product to use this new iron delivery system.”

Feramax[®] Pd is made with a homogeneous polysaccharide, Polydextrose, linked to ferric (Fe³⁺) elemental iron to form the proprietary iron complex, Polydextrose Iron Complex (“PDIC”). This formulation differs from the current Feramax[®] formulation which uses a heterogeneous mixture of polysaccharides in the iron complex forming a Polysaccharide Iron Complex (“PIC”). The change in formulation of Feramax[®] provides a more uniform molecular structure.

Feramax[®] Pd’s new enhanced delivery system, combined with its confirmed efficacy and good tolerability, make it the ideal choice for iron deficient patients who cannot tolerate ferrous salt-based oral iron alternatives.

Canadian healthcare providers and patients can confidently rely on the new formulation to provide the same benefits that have made Feramax[®] the #1 recommended iron supplement by Canadian Pharmacists and Physicians for five consecutive years, including 2020 (*Pharmacy Practice+ and Profession Santé 2020 / The Medical Post and Profession Santé 2020 – Survey on OTC Counselling and Recommendations*).

Feramax[®] Pd is Vegan Certified and is recognized by the Society of Obstetricians and Gynaecologists of Canada.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty/hospital, and international business units.

As of the date of this press release, the Company has 12,808,600 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

For further information please contact:

Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web: www.biosyent.com

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.